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ABSTRACT 
Laboratory testing is important in the diagnosis and monitoring of liver injury and disease. Current liver tests in-
clude plasma markers of injury (e.g. aminotransferases, γ-glutamyl transferase, and alkaline phosphatase), mark-
ers of function (e.g. prothrombin time, bilirubin), viral hepatitis serologies, and markers of proliferation (e.g. α-
fetoprotein). Among the injury markers, the alanine and aspartate aminotransferases (ALT and AST, respective-
ly) are the most commonly used. However, interpretation of ALT and AST plasma levels can be complicated. 
Furthermore, both have poor prognostic utility in acute liver injury and liver failure. New biomarkers of liver in-
jury are rapidly being developed, and the US Food and Drug Administration the European Medicines Agency 
have recently expressed support for use of some of these biomarkers in drug trials. The purpose of this paper is 
to review the history of liver biomarkers, to summarize mechanisms and interpretation of ALT and AST eleva-
tion in plasma in liver injury (particularly acute liver injury), and to discuss emerging liver injury biomarkers 
that may complement or even replace ALT and AST in the future.  
 
Keywords: Liver injury, liver disease, diagnostics, biomarkers, mechanistic biomarkers 
 
 
 
 
INTRODUCTION 
Laboratory testing is important in the di-
agnosis of liver disease and the differentia-
tion of etiology. The current battery of liver 
tests can roughly be divided in three: 1) indi-
cators of liver function, 2) indicators of liver 
injury and 3) viral hepatitis serologies. Tests 
of liver function comprise coagulation tests 
(e.g. prothrombin time, INR), serum biliru-
bin and serum protein (total or albumin), 
while liver injury tests include serum alanine 
aminotransferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase 
(ALP), γ-glutamyl transferase (GGT), lactate 
dehydrogenase (LDH) and sometimes glu-
tamate dehydrogenase (GLDH). Alpha-
fetoprotein (AFP) stands alone in a fourth 
category as a biomarker of hepatocyte prolif-
eration (e.g. liver development, hepatocellu-
lar carcinoma, liver regeneration). Among 
the liver injury markers, ALT and AST are 
probably the most commonly used in both 
clinical diagnosis and research involving liv-
er damage. However, there is some confu-
sion about the proper use and interpretation 
of these aminotransferases (Senior, 2012). 
Furthermore, emerging data have highlighted 
the limitations of serum aminotransferases 
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for early detection of injury and for predic-
tion of patient outcome.  
Recent years have seen the proliferation 
of liver injury biomarkers, many with the po-
tential to replace or at least complement se-
rum aminotransferases for certain applica-
tions (Amacher et al., 2013; McGill and 
Jaeschke, 2014). Considerable progress has 
been made in the development of novel 
mechanistic biomarkers (McGill and Jaesch-
ke, 2014), markers of inflammation (McGill 
and Jaeschke, 2014), extracellular RNA-
based biomarkers (Starkey Lewis et al., 
2012; Amacher et al., 2013; McGill and 
Jaeschke, 2015), and various others (Davern 
et al., 2006; Craig et al., 2013; Prima et al., 
2013; McGill et al., 2014a, b, c; We-
erasinghe et al., 2014). It has been suggested 
that one or more of these markers will re-
place or supplement current biomarkers for 
some purposes in the near future. In fact, the 
US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) 
both expressed support for several organiza-
tions interested in developing new drug-
induced liver injury biomarkers, including 
the Safer and Faster Evidence-based Transla-
tion network and the Drug-Induced Liver In-
jury Network. Thus, it seems appropriate to 
review what is known about the biology and 
clinical utility of the aminotransferases, what 
we know about the mechanisms of serum 
aminotransferase elevation and the proper in-
terpretation of serum levels, and what the fu-
ture may hold for biomarkers in the diagno-
sis and monitoring of liver injury.  
 
REACTIONS CATALYZED BY THE 
AMINOTRANSFERASES 
Both ALT and AST catalyze the transfer 
of an amino group from an amino acid to α-
ketoglutarate. The amino acids are L-alanine 
and L-aspartate and the reaction products are 
L-glutamate and either pyruvate or oxaloace-
tate, respectively (Figure 1A). The overall 
effect is exchange of an amino group and a 
keto group. Pyridoxal 5’-phosphate (PLP; 
vitamin B6 derivative) serves as a coenzyme 
in both reactions. It is important to note that  
 
Figure 1: Functions of ALT and AST. (A) Both 
alanine and aspartate aminotransferases (ALT 
and AST, respectively) catalyze the conversion 
of alpha-ketoglutarate (a-KG) and an amino acid 
to glutamate and another product. In the case of 
ALT, the amino acid and product are alanine and 
pyruvate. In the case of AST, the amino acid and 
product are aspartate and oxaloacetate (OAA). 
(B) The glucose-alanine cycle. (C) The malate-
aspartate shuttle. IMM, inner mitochondrial 
membrane. 
 
these reactions can be reversed. Because the 
reactants and products are important for nu-
merous cell processes, both ALT and AST 
have diverse physiological functions aside 
from their obvious roles in amino acid me-
tabolism. For example, they are also im-
portant for energy homeostasis. Arguably, 
the most important role of ALT is in the ala-
nine-glucose cycle (Figure 1B). In muscle, 
ALT converts pyruvate to the amino acid al-
anine using an amino group from glutamate. 
Alanine enters circulation and is taken up by 
the liver, where ALT in hepatocytes can 
convert it back to pyruvate which can be 
used to make glucose. This system is espe-
cially important for glucose regulation dur-
ing stressful conditions such as fasting or 
vigorous exercise. It has also been suggested 
that the mitochondrial isoform of ALT is 
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particularly important in gluconeogenesis in 
some cases (McCommis et al., 2015). The 
most important physiological function of 
AST may be maintenance of the 
NAD+/NADH ratio within cells. AST is a 
critical partner in the malate-aspartate shut-
tle, which oxidizes NADH in the cytosol and 
reduces NAD+ in the mitochondrial matrix 
to facilitate glycolysis and electron transport, 
respectively (Figure 1C).  
 
BRIEF HISTORY OF CLINICAL  
LIVER TESTS 
Prior to the advent of liver enzyme 
measurement, assessment of liver health was 
limited to clinical examination (e.g. jaundice, 
abdominal pain) and laborious tests of liver 
function. For example, direct bilirubin could 
be measured as early as 1913 using the van 
den Bergh reaction. The clearance of dyes 
such as bromosulphthalein, (Rosenthal and 
White, 1925) as well as formation of me-
tabolites of compounds such as benzoic acid 
(Quick, 1936), provided an indication of the 
ability of the liver to metabolize and excrete 
xenobiotics. The galactose tolerance test as-
sessed the ability of the liver to convert ga-
lactose to glycogen (Bauer, 1906; Shay et al., 
1931). Flocculation of samples after mixing 
with specific reagents, such as cephalin-
cholesterol complexes prepared from sheep 
brain (Hanger, 1939), could be examined to 
measure changes in serum protein composi-
tion caused by liver dysfunction. Coagula-
tion time could also be measured. Unfortu-
nately, most of these tests were relatively 
time-consuming, or were not broadly appli-
cable to many liver diseases. Furthermore, 
the large functional capacity of the liver and 
its ability to regenerate mean that many of 
these tests would not be expected to give ab-
normal results except in cases of very severe 
or prolonged liver disease. Thus, sensitivity 
was probably limited for most of these tests. 
Although ALP had been measured in se-
rum in various diseases as early as 1930 
(Kay, 1930), changes in other liver enzyme 
levels, including aminotransferase levels, in 
serum from patients with liver injury were 
not described until much later. At the time, it 
was generally thought that intracellular en-
zymes were anchored to cell organelles and 
could not be released even after plasma 
membrane damage (Ettre and Zlatkis, 1979). 
It took the boldness of a private practice 
physician with only limited laboratory train-
ing and a medical student assistant to pursue 
the possibility. Karmen et al. (1955) were the 
first to report elevated ALT and AST in se-
rum during liver injury. They observed ami-
notransferase increases in a single patient 
with acute hepatitis and two others with cir-
rhosis in the early 1950s (Karmen et al., 
1955). The authors were specifically inter-
ested in investigating the possibility of using 
these enzymes as markers of myocardial in-
farction, but found that they could be elevat-
ed in other disease states as well. Around the 
same time, De Ritis et al. (1955) demonstrat-
ed an increase in both enzymes in serum 
from viral hepatitis patients. Interestingly, 
Karmen and Wróblewski (1955) may have 
been the first to use the term “biochemical 
biopsy,” which was used in reference to the 
aminotransferases (Wróblewski, 1958). 
Initially, the measurement of aminotrans-
ferase activity could also be time-consuming. 
In the study by Karmen et al. (1955), paper 
chromatography was used to separate gluta-
mate produced by the reaction of either en-
zyme with α-ketoglutarate and alanine or as-
partate. The glutamate spots were then cut 
from the paper and the glutamate was ex-
tracted and measured with a colorimetric 
test. In an appendix to their groundbreaking 
study, Karmen et al. (1955) introduced a 
coupled enzyme reaction for AST measure-
ment that is the basis for many modern as-
says. A very similar test was later developed 
for ALT (Wróblewski and LaDue, 1956). In 
the former case, the oxaloacetate produced 
by AST was reduced to malate by malate de-
hydrogenase, consuming NADH in the pro-
cess. In the latter case, pyruvate produced by 
ALT was further reduced by LDH, also con-
suming NADH. The depletion of NADH 
over time can be monitored by loss of ab-
sorbance at 340 nm and these data can be 
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used to calculate activity. Coupled reactions 
dramatically reduced the amount of time 
needed to measure these enzymes (Ettre and 
Zlatkis, 1979).  
Measurement of transaminases was soon 
adopted in clinical laboratories. Although 
follow-up experiments revealed that AST 
was consistently elevated in patients with 
liver disease (Wróblewski and LaDue, 1955; 
Jervis et al., 1956), it was found that ALT is 
a better indicator of liver damage because, 
unlike AST, its activity is much greater in 
liver than in muscle (LaDue and Wroblew-
ski, 1956). Overall, the specificity of ALT 
for the liver and availability of a relatively 
fast method to measure it made it appealing 
for clinical use. Unfortunately, while mark-
ers of injury in other organs, such as heart 
and kidney, seem to be constantly evolving, 
aside from the introduction of GGT as a 
marker of liver disease in the 1960s (Szcze-
klik et al. 1961) there has been very little 
change in biomarkers of liver injury in clini-
cal use since the introduction of AST and 
ALT, in contrast to biomarkers for other 
forms of tissue injury including acute myo-
cardial damage (Figure 2). 
 
 
Figure 2: Timeline of biomarker development for 
both acute myocardial injury and liver injury 
(1950 – 2010).  
AST, aspartate aminotransferase 
ALT, alanine aminotransferase 
LDH, lactate dehydrogenase 
GGT, gamma-glutamyl transpeptidase 
CK, creatine kinase 
CK-MB, creatine kinase-MB (myocardial isoform) 
EL, electrophoresis for LDH and CK 
Trop, troponin 
Hs-Trop, high sensitivity troponin 
 
 
MECHANISMS AND INTERPRETA-
TION OF ALT/AST ELEVATION 
It is generally thought that aminotrans-
ferase elevations are due to cell damage with 
plasma membrane disruption. This is sup-
ported by the finding that serum ALT levels 
are initially low after treatment with inducers 
of hepatocyte apoptosis, but increase later in 
the course of injury. Apoptotic cell death can 
be thought of as cell implosion; a controlled 
process with minimal release of proteins into 
the extracellular space. However, oncotic ne-
crosis, which can be thought of as cell explo-
sion, can occur in some cells secondarily af-
ter induction of apoptosis. The hallmarks of 
apoptosis (e.g. cell shrinkage, chromatin 
condensation, apoptotic body formation) are 
clearly observable in the liver in hepatocyte 
apoptosis models during the early phase of 
injury when there is no significant elevation 
in serum ALT (Leist et al., 1995; Lawson et 
al., 1998; Bajt et al., 2000). The serum ALT 
activity dramatically increases during the lat-
er phase, when secondary necrosis occurs ei-
ther as a result of direct hepatocyte damage 
or inflammation (Leist et al., 1995; Lawson 
et al., 1998; Bajt et al., 2000). 
Although plasma membrane damage and 
protein leakage is probably the most com-
mon reason for elevated serum ALT, there is 
evidence that other mechanisms can be in-
volved (Table 1). It has been suggested that 
membrane blebs containing cytosolic com-
ponents form during ischemia-reperfusion 
injury (IRI) of the liver and that these protru-
sions can rupture to release aminotransferas-
es without cell death (Lemasters et al., 1981; 
Kamiike et al., 1989; Gores et al., 1990). 
This was based in part on evidence from mi-
croscopy (Lemasters et al., 1981) and on the 
finding that the cytosolic isoform of AST is 
released early in IRI, while the mitochondri-
al isoform does not increase in serum until 
later and correlates better with the extent of 
liver necrosis (Kamiike et al., 1989).  
Another contributor to increased serum 
aminotransferase levels in some cases is in-
duction of expression. It has been known for 
some time that microsomal enzyme-inducing 
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drugs, including alcohol, can increase tissue 
expression and serum levels of GGT (Whit-
field, 2001). Experimental work has also re-
vealed that ALT and AST activity are in-
creased in livers of mice treated with carbon 
tetrachloride (CCl4), suggesting an increase 
in expression (Pappas, 1980, 1986). Fur-
thermore, post-treatment with the protein 
synthesis inhibitor cyclohexamide was 
shown to prevent this aminotransferase in-
duction and significantly reduce serum levels 
of both enzymes (Pappas, 1986, 1989). Im-
portantly, cyclohexamide did not increase 
survival, demonstrating that the reduced 
aminotransferase levels were not simply a 
result of protection against CCl4 (Pappas, 
1986; 1989). It was suggested that the in-
crease in ALT and AST expression after 
CCl4 treatment could be partially explained 
by liver cell regeneration (Pappas, 1989), but 
little evidence for that was presented. Over-
all, these findings support the idea that even 
large increases in serum levels of ami-
notransferases can be due, in part, to induc-
tion of expression.  
At least two mechanisms have been pro-
posed for regulation of ALT expression. It 
has been known for decades that some pa-
tients taking fibrates have asymptomatic in-
creases in serum ALT. Fibrates are peroxi-
some-proliferator-activated receptor-α 
(PPARα) agonists. This knowledge led to the 
hypothesis that PPARα regulates expression 
of ALT and AST, which was supported by 
the finding that treatment with fenofibrate 
induced expression of the cytosolic isoforms 
of both enzymes in human hepatoma cells 
(Edgar et al., 1998). Interestingly, fenofibrate 
reduced expression of the cytosolic ami-
notransferases in mice and this effect was ab-
rogated by PPARα deficiency (Edgar et al., 
1998). The latter finding supported the im-
portance of PPARα in the expression of ami-
notransferases, while demonstrating a clear 
species difference in response to PPARα ag-
onists. It was later shown that the cytosolic 
and mitochondrial isoforms of ALT (ALT1 
and ALT2, respectively) are the products of 
two different genes (GPT1 and GPT2) in 
both mice and humans (Sohocki et al., 1997; 
Yang et al., 2002; Jadhao et al., 2004). GPT1 
is located on chromosome 8 while GPT2 is 
on chromosome 16 (Sohocki et al., 1997; 
Yang et al., 2002). The cytosolic and mito-
chondrial isoforms of AST are also encoded 
by different genes (Pol et al., 1989). GOT1 is 
located on chromosome 10, while GOT2 is 
on chromosome 16 and possibly also encod-
ed in part on chromosomes 1 and 12. ALT1 
is now known to be the dominant isoform of 
ALT in the liver (Lindblom et al., 2007). 
Consistent with earlier work, further studies 
revealed that PPARα specifically controls 
expression of the GPT1 gene (Thulin et al., 
2008). Fenofibrate treatment induced expres-
sion of ALT and increased binding of 
PPARα to the GPT1 promoter in cultured 
human hepatocytes (Thulin et al., 2008). 
Furthermore, deletion of the PPAR binding 
site in the promoter reduced fenofibrate-
induced expression of GPT1 (Thulin et al., 
2008). Altogether, there is strong evidence 
that PPARα plays a role in regulation of both 
ALT and AST levels, particularly ALT1. 
Other mechanisms seem to regulate GPT2 
expression, such as the PI3K-ATF4 axis 
(Hao et al., 2016). 
Recent work has shown that expression 
of ALT and AST can also be controlled by 
IRE1α/c-Jun signaling (Josekutty et al., 
2013). It was found that treatment with an 
inhibitor of the microsomal triglyceride 
transfer protein (MTP) increased levels of 
ALT1 and AST1 in both lysates and medium 
from Huh-7 cells, and knockdown of either 
IRE1α or c-Jun prevented these increases 
(Josekutty et al., 2013). It is clear from these 
data that increased expression of ALT and 
AST genes can contribute to elevated serum 
levels. This may partially explain the wide 
variation in serum aminotransferase activi-
ties observed in humans during liver injury 
and the poor correlations of serum ami-
notransferases with extent of liver necrosis 
and patient outcome (Björnsson et al., 2006; 
Antoine et al., 2012; McGill et al., 2014c). 
Interestingly, it has been known for some 
time that various nutritional factors, such as 
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protein intake, can affect aminotransferase 
levels (Rosen et al., 1959). Obesity and stea-
tosis have also been shown to cause a minor 
induction of ALT2 in the liver (Jadhao et al., 
2004; Aubert et al., 2012). With increased 
obesity rates in humans, it is tempting to 
speculate that this phenomenon also contrib-
utes to the variation in serum ALT in liver 
injury patients.    
Overall, although cell death and plasma 
membrane damage are likely the dominant 
causes of serum aminotransferase elevations, 
other mechanisms can clearly influence the 
results. The actual mechanisms of release in 
the case of asymptomatic ALT or AST in-
creases have not been well-studied. Conceiv-
ably, extracellular vesicles, like microvesi-
cles and exosomes, or even protein secretion, 
could be involved. Furthermore, although it 
is usually assumed that baseline levels of se-
rum aminotransferases are due to normal 
turnover of hepatocytes, it also possible that 
other mechanisms play a role.  
It should be noted that elevations in se-
rum aminotransferase activities don’t always 
involve increased release or expression. 
Complexes of serum enzymes with immuno-
globulins or other proteins can also lead to 
moderately increased levels. Such “macroen-
zymes” can protect the serum enzymes from 
degradation, prolonging their half-lives and 
allowing them to accumulate to high concen-
trations. In this way, ALT and AST can be 
elevated even with normal release. A number 
of cases of aminotransferase macroenzymes 
have been described in the literature 
(Konttinen et al., 1978; Kajita et al., 1978; 
Briani et al., 2003). Macroenzymes should 
be considered in cases of otherwise asymp-
tomatic ALT or AST elevations in serum, 
especially if only one of the two is increased. 
One study found that approximately 13 % of 
cases of AST elevation without concomitant 
ALT increase are due to macroAST (Mori-
yama et al., 1990). 
 
 
 
 
Table 1: Mechanisms of plasma ALT or AST  
elevation 
Mechanism References 
Oncotic necrosis 
Leist et al., 1995;  
Lawson et al., 1998;  
Bajt et al., 2000 
Membrane blebbing 
Lemasters et al., 1981; 
Kamiike et al., 1989;  
Gores et al., 1990 
Increased expression
Pappas et al., 1980;  
1986; 1989;  
Aubert et al., 2012 
Macroenzymes 
Konttinen et al., 1978; 
Kajita et al., 1978;  
Moriyama et al., 1990; 
Briani et al., 2003 
 
 
THE FUTURE OF LIVER INJURY  
BIOMARKERS 
There has been tremendous growth in in-
terest in the development of new biomarkers 
of liver injury over the last decade. The three 
main drivers of this have been 1) the need 
during early drug trials for sensitive non-
invasive biomarkers to identify new drugs 
that have the potential to cause idiosyncratic 
hepatotoxicity in a larger population, 2) the 
need for biomarkers to predict outcome in 
the clinical setting in which serious liver in-
jury has already occurred, and 3) a desire for 
non-invasive biomarkers that are useful for 
translation of pathophysiological mecha-
nisms from rodents to humans. The most 
common model used for identification of 
new biomarkers for all three purposes is the 
acetaminophen (APAP) overdose model. 
Although the injury caused by APAP is not 
idiosyncratic and its utility for the first pur-
pose may be somewhat questionable, the 
APAP model is both experimentally conven-
ient and clinically relevant. APAP hepato-
toxicity can be induced in mice with a single 
large dose, and has a rapid disease course. In 
addition, APAP overdose is a common cause 
of acute liver failure (ALF) and ALF-related 
deaths in humans (Lee, 2008) and it is easier 
to obtain clinical specimens from patients 
with liver injury caused by APAP than by 
other drugs. For these reasons, most liver in-
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jury biomarker research has been done using 
samples from mice or humans after APAP 
overdose. Unfortunately, few studies have 
been designed in such a way to permit calcu-
lation of positive and negative predictive 
values (PV). Nevertheless, nearly every 
study comparing a novel biomarker of liver 
injury with ALT and/or AST has found evi-
dence that these new biomarkers perform 
better than the aminotransferases for detec-
tion of liver injury and prediction of out-
come. The major categories of emerging bi-
omarkers are summarized in Table 2 and de-
scribed below. 
  
Mitochondrial damage biomarkers 
Mitochondrial damage and dysfunction 
are thought to be common mechanisms of 
drug hepatotoxicity (Pessayre et al., 2012) 
and are especially important in APAP toxici-
ty (Jaeschke et al., 2012). Several bi-
omarkers of mitochondrial damage have 
been identified or suggested. It has been 
shown that the mitochondrial enzyme gluta-
mate dehydrogenase (GLDH) and mitochon-
drial DNA (mtDNA) are increased in circu-
lation of humans after APAP overdose and 
hypoxic hepatitis, and that these markers are 
specific for injury involving mitochondrial 
damage (McGill et al., 2012; McGill et al., 
2014c; Weemhoff et al., 2016). More recent 
research has identified acylcarnitines 
(McGill et al., 2014b; Bhattacharyya et al., 
2014), and the mitochondrial matrix en-
zymes carbamoyl phosphate synthetase-1 
(CPS1) (Weerasinghe et al., 2014; Brown et 
al., 2014) and ornithine carbamoyltransferase 
(Furihata et al., 2016) as possible biomarkers 
of mitochondrial dysfunction. Although all 
of these biomarkers appear to be useful for 
translational research (McGill et al., 2012; 
2014c), their clinical utility so far appears to 
be limited. Although several of them are 
higher in serum from non-survivors of APAP 
overdose than survivors, all those tested have 
relatively low sensitivity and specificity for 
patient outcome (e.g. 77 % and 76 %, re-
spectively, for mtDNA at an optimal cutoff 
of 14 ng/mL) (McGill et al., 2014c). Never-
theless, they represent a first step toward de-
velopment of biomarkers that predict out-
come better than current liver injury tests 
(McGill et al., 2014c), as serum ALT levels 
show no association whatsoever with out-
come (Björnsson et al., 2006; Antoine et al., 
2012; McGill et al., 2014c). 
 
Cell death mode biomarkers  
The two major forms of cell death are 
oncotic necrosis and apoptosis, and bi-
omarkers are available for the measurement 
of each. Currently, the most popular circulat-
ing biomarkers of cell death mode are the 
full-length and caspase-cleaved forms of 
keratin-18 (K18). Importantly, there is evi-
dence that K18 is useful for prediction of pa-
tient outcome. Elevated serum levels of K18 
at the time of presentation have been shown 
to predict later development of liver injury in 
early-presenting APAP overdose patients 
with positive PV of 64 % and 73 % for the 
full-length and apoptotic forms, respectively, 
and negative PV > 85 % (only 86.5 % for 
full-length K18), using optimal cutoffs (An-
toine et al., 2013). Although these values 
may not be good enough for these markers to 
serve as the major criteria in patient triage 
(because the antidote for APAP, N-
acetylcysteine, is effective and relatively in-
nocuous, it would be particularly bad to miss 
~15 % of patients in need of treatment), they 
are much better than the values for ALT 
(negative and positive PV of 36 % and 85 %, 
respectively). Furthermore, significant asso-
ciations between K18 and another cell death 
biomarker, high-mobility group box 1 pro-
tein (HMGB1), with poor outcome were ob-
served (Antoine et al., 2012). Interestingly, 
the greatest positive and negative PVs of any 
biomarker tested for early detection of liver 
injury after APAP overdose were for 
HMGB1, at 91 % and 87 % (Antoine et al., 
2013). Caspase activity and caspase cleavage 
can also be measured in circulation as mark-
ers of apoptotic cell death (McGill et al., 
2012; Woolbright et al., 2015), but their clin-
ical utility has not been assessed. 
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DNA damage biomarkers 
DNA damage can be assessed by ladder-
ing or smearing on an agarose gel, or by de-
tection of nucleosomes by immunoassay. 
Nuclear DNA fragments have been measured 
using the latter approach in serum and plas-
ma from patients with APAP-induced liver 
injury (McGill et al., 2012, 2014c) and acute 
liver injury due to other etiologies (Craig et 
al., 2011; Weemhoff et al., 2016) and are 
generally increased over healthy controls. 
They also appear to be higher in non-
survivors compared with survivors (McGill 
et al., 2014c); however, sensitivity and speci-
ficity are lacking. 
 
Nucleic acid biomarkers 
The relatively recent discovery that mi-
croRNAs (miRNA) can be detected in circu-
lation has led to an explosion in interest in 
miRNA and other nucleic acids as non-
invasive disease biomarkers (McGill and 
Jaeschke, 2015). Multiple studies have re-
ported increases in miR-122, miR-192, miR-
125b and other miRNAs in serum or plasma 
after APAP overdose in both humans and 
mice (Ward et al., 2014; Krauskopf et al., 
2015; Yang et al., 2015; McGill and Jaesch-
ke, 2015), and some of these miRNA species 
appear to be very sensitive for drug hepato-
toxicity in some cases (Dear et al., 2014). 
Positive and negative PV of miR-122 for 
early detection of hepatotoxicity after APAP 
overdose were similar to K18 variants at 
73 % and 87 %, respectively (Antoine et al., 
2013), and miR-122 is elevated in APAP-
induced liver injury patients with poor out-
come (Antoine et al., 2012). Importantly, the 
use of miRNA biomarkers may go beyond 
detection of liver injury and prognosis in liv-
er disease; circulating miRNA profiles may 
also be useful for diagnosis of the underlying 
cause of the injury. For example, circulating 
miRNA profiles have been shown to differ-
entiate between APAP hepatotoxicity and 
hypoxic hepatitis (Ward et al., 2014).  
 
Other biomarkers 
Changes in a variety of other serum and 
plasma biomarkers have recently been re-
ported in liver injury patients. For example, 
argininosuccinate synthetase appears to in-
crease earlier than ALT in acute liver injury 
and may be more sensitive (McGill et al., 
2014a; Qin et al., 2016). Certain bile acids 
are increased in acute liver injury (Wool-
bright et al., 2014; Luo et al., 2014). Even 
markers typically used to diagnose or follow 
conditions other than liver injury have been 
shown to be elevated in circulation of liver 
injury patients and can be useful for predic-
tion of outcome, including kidney injury 
molecule-1 (KIM-1) (Antoine et al., 2015) 
and troponin I (Moore et al., 2013). Other 
proposed biomarkers include aldolase B (Qin 
et al., 2016) and macrophage colony-
stimulating factor 1 (Stutchfield et al., 2015). 
Panels of biomarkers designed to maximize 
sensitivity and specificity have also been 
suggested (McGill et al., 2014c; Qin et al., 
2016). Finally, various cytokines and in-
flammatory markers have been shown to be 
elevated in circulation of patients with liver 
injury, including IL-6, IL-8 (James et al., 
2005) and acetylated HMGB1 (Antoine et 
al., 2012; Weemhoff et al., 2016). 
 
Table 2: Examples of emerging liver injury  
biomarkers 
Category Biomarkers 
Mitochondrial damage 
biomarkers 
GLDH, mtDNA,  
acylcarnitines,  
CPS1 
Cell death  
biomarkers 
Full-length and  
caspase-cleaved K18,  
HMGB1, miR-122 
DNA damage  
biomarkers Nuclear DNA fragments
Other nucleic acid  
biomarkers 
miR-122 and  
other miRNAs 
Inflammation  
biomarkers 
Acetylated HMGB1,  
various cytokines 
Other biomarkers 
Bile acids, ASS,  
CSF1, KIM1,  
aldolase B 
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CONCLUSIONS 
The purpose of this review is not to eulo-
gize the aminotransferases, or any other 
markers of liver injury. Certainly, they will 
remain important tools for the diagnosis and 
study of liver injury in the future. Rather, the 
purpose is to provide the reader with a better 
understanding of the aminotransferases and 
to discuss emerging biomarkers that could 
replace or complement them in the future. 
It’s clear that several novel liver injury bi-
omarkers have better clinical performance 
than ALT and AST for early detection of liv-
er injury and for prediction of outcome. 
However, better predictive values are desira-
ble (improved NPV for patient triage and 
improved PPV for poor outcome after liver 
injury develops) before routine clinical use. 
The latter may be achieved in part through 
the use of multi-biomarker panels to maxim-
ize sensitivity and specificity, or through 
discovery of entirely new markers of liver 
injury. There is also evidence that certain 
markers, such as GLDH, mtDNA, nuclear 
DNA fragments, K18 and HMGB1 can indi-
cate specific pathophysiological mecha-
nisms, and this makes them useful for trans-
lational research. Finally, additional studies 
are needed to determine if any of these 
emerging biomarkers are useful for predic-
tion of idiosyncratic toxicity in drug trials.   
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